Economic evaluation of tandem mass spectrometry screening in California

被引:37
作者
Feuchtbaum, L [1 ]
Cunningham, G [1 ]
机构
[1] Calif Dept Hlth Serv, Genet Dis Branch, Richmond, CA 94804 USA
关键词
newborn screening; economics; cost-utility;
D O I
10.1542/peds.2005-2633G
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
OBJECTIVE. On the basis of California's experience implementing a pilot tandem mass spectrometry (MS/MS) screening program, an economic evaluation was conducted to determine the economic benefits and costs of a statewide MS/MS screening program. METHODS. Cost-effectiveness, benefit/cost, and cost-utility analyses were conducted with a base-case set of assumptions. The base-case assumptions were varied by using a set of more-favorable and less-favorable assumptions to test the robustness of the analysis findings. RESULTS. The total estimated, annualized, incremental costs of MS/MS screening of 540 000 births in California were nearly $5.7 million; 83 affected newborns would be identified. Screening would reduce the expected lifetime costs of medical care for affected newborns by $7.2 million ($9.0 million in the best-case scenario and $1.8 million in the worst-case scenario). When all program costs and savings were considered, screening saved $1.5 million ($3.4 million saved in the best-case scenario and $3.8 million additional costs in the worst-case scenario). With only incremental program costs, the cost per life saved was $ 708 000 and the cost per case detected was $68 000. With consideration of the projected lifetime medical care costs, the total cost per case detected was $ 132 000. MS/MS screening produced a benefit/cost ratio of $9.32 ($11.67 with the best-case set of assumptions and $4.34 with the worst-case set of assumptions). In this analysis, the benefits of screening exceeded total program costs by $47.1 million (the net incremental benefit). In the worst-case scenario, the net incremental benefit of screening was $18.9 million. Screening saved 949 quality-adjusted life-years (QALYs) and saved $ 1628 per QALY in the base case analysis. Under the worst-case scenario, the cost per QALY was $14 922. CONCLUSIONS. We found that the benefits of MS/MS screening outweighed the costs and that the net benefits were significant and robust in various scenarios with various conservative underlying assumptions.
引用
收藏
页码:S280 / S286
页数:7
相关论文
共 10 条
[1]  
ARLAS E, 2003, NATL VITAL STAT REP, V51, P1
[2]  
Bennett JE, 2000, ARCH PEDIAT ADOL MED, V154, P43
[3]   The influence of intellectual disability on life expectancy [J].
Bittles, AH ;
Petterson, BA ;
Sullivan, SG ;
Hussain, R ;
Glasson, EJ ;
Montgomery, PD .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2002, 57 (07) :M470-M472
[4]  
Blomquist G.C., 2004, Rev. Econ. Househ., V2, P89, DOI DOI 10.1023/B:REHO.0000018024.53114.3A
[5]  
CARROLL AE, 2006, PEDIATRICS, P117
[6]   Willingness to pay for a quality-adjusted life year: In search of a standard [J].
Hirth, RA ;
Chernew, ME ;
Miller, E ;
Fendrick, AM ;
Weissert, WG .
MEDICAL DECISION MAKING, 2000, 20 (03) :332-342
[7]  
Honeycutt A., 2004, MMWR, V53, P57
[8]   Newborn screening with tandem mass spectrometry: Examining its cost-effectiveness in the Wisconsin newborn screening panel [J].
Insinga, RP ;
Laessig, RH ;
Hoffman, GL .
JOURNAL OF PEDIATRICS, 2002, 141 (04) :524-531
[9]   Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry:: Results, outcome, and implications [J].
Schulze, A ;
Lindner, M ;
Kohlmüller, D ;
Olgemöller, K ;
Mayatepek, E ;
Hoffmann, GF .
PEDIATRICS, 2003, 111 (06) :1399-1406
[10]  
*US EPA, 2004, 45203001 EPA